|
|
|
|
(China) ScinoPharm breaks ground at new manufacturing facility in China
|
15 November, 2009
ScinoPharm Taiwan Ltd., a global supplier of active pharmaceutical ingredients (APIs), has started construction of a new plant on a 66670 square meter site in Changshu, Jiangsu province in China.
In an announcement last week, the Tainan, Taiwan-headquartered company said that the plant, slated for completion in 2011, will include a R&D centre and production plants fully compliant with US and international GMP standards. It will initially be used for the production of GMP grade pharmaceutical intermediates initially, and later be equipped to handle API production.
"The new site is part of ScinoPharm's long-term strategy to bolster its presence in China. Additional manufacturing and R&D facilities will complement our existing experience in selling quality APIs in regulated markets. The Changshu plant will serve as a launching pad for the rapidly expanding Chinese pharmaceutical market as well as a backup site to our customers," said Dr. Jo Shen, President and CEO of ScinoPharm.
"The Changshu facilities will help ScinoPharm's vertical integration with high quality intermediates, and will ensure final API products are of the highest quality and safety, yet at lower costs," added Dr. Hardy Chan, Executive Vice President and CSO of ScinoPharm.
ScinoPharm's investment in Changshu will also address the increasing number of multinational companies shifting their drug development research and clinical trials to China.
"They need supporting companies, like ScinoPharm, that are beyond medicinal chemistry companies and are knowledgeable about clinical API development, has experience handling FDA inquiries, and also inspections," commented Chan.
|
|
|
|
First pages: 1 2 3 4 5 6 7 8 9 10 Total pages:220 下一頁
|
|
|
| |
